Trials / Completed
CompletedNCT00856908
Safety and Tolerability After Four Weeks of Treatment With AZD1656 in Patients With Type 2 Diabetes
A Randomised, Single-Blind, Placebo-Controlled, Phase IIa Study to Assess the Safety and Tolerability After Multiple Oral Doses of AZD1656 During Four Weeks in T2DM Subjects Treated With Insulin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 30 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the 1 month safety and tolerability after multiple oral doses of AZD1656 in patients with Type 2 Diabetes Mellitus Treated with Insulin
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AZD1656 | Tolerable dose given twice daily |
| DRUG | Placebo | Tolerable dose given twice daily |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-03-06
- Last updated
- 2012-12-06
- Results posted
- 2012-11-26
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00856908. Inclusion in this directory is not an endorsement.